Findings

What do systematic reviews say?

149 questions · 157 findings · 43 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 2.5%GRADE not reported 6 · 3.8%Very low 10 · 6.4%Low 71 · 45.2%Moderate 48 · 30.6%High 18 · 11.5%

Selexipag vs placebo

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

RAP · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Selexipag vs placebo

Dyspnea · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Moderate

Prostacyclin vs control

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 868 participants
Low

Prostacyclin vs control

RAP · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1060 participants
Moderate

Prostacyclin vs control

Dyspnea · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1521 participants
Low

LABA/LAMA vs placebo

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · Adults with COPD

1 finding from 1 review

Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for… 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 4952 participants
High

Antibiotics vs placebo or usual care

Symptom score at 10 days. Measured on a 7‐point scale (0 to 6) ; lower score denotes fewer symptoms · acute asthma exacerbation

1 finding from 1 review

Antibiotics for exacerbations of asthma 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2 participants
Moderate

Summary of findings for AMBMT vs PR

Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 249 participants
Low

Summary of findings for AMBMT vs PR

CAT score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 74 participants
Low

Summary of findings for AMBMT vs PR

Dyspnoea ‐ change in mMRC Scale 0 to 4. Lower is better and 1 unit is a clinically important difference · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 127 participants
Very low

Summary of findings for AMBMT vs PR

Change in dyspnoea score · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 139 participants
Very low

Summary of findings for AMBMT + PR vs PR

Units of SGRQ change from baseline · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Active mind‐body movement therapies as an adjunct to or in comparison with pulmonary rehabilitation for people with… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 192 participants
Moderate

LABA/LAMA vs LAMA

Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (moderate certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 0.99 [0.57, 1.72]
7 studies · 4937 participants
Moderate

LABA/LAMA vs LAMA

Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LAMA (moderate certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 1.23 [0.84, 1.81]
22 studies · 18538 participants
Moderate

LABA/LAMA vs LABA

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA probably leads to lower moderate to severe exacerbations: low‐risk population compared with LABA (moderate certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 0.77 [0.62, 0.97]
5 studies · 2488 participants
Moderate

LABA/LAMA vs LABA

Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in severe exacerbations: low‐risk population compared with LABA (moderate certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 0.78 [0.55, 1.12]
6 studies · 2898 participants
Moderate

LABA/LAMA vs LABA

Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in pneumonia: low‐risk population compared with LABA (moderate certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 1.54 [0.95, 2.49]
10 studies · 8252 participants
Moderate

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 0.86 [0.65, 1.14]
6 studies · 4315 participants
Moderate

LABA/ICS vs LAMA

Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/ICS showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).

1 finding from 1 review

Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a… 2018 · Cochrane Headline outcomes only
OR 0.63 [0.24, 1.66]
1 study · 623 participants
Low